THE RESPONSIVENESS OF CHILDHOOD/ADOLESCENT CHRONIC MYELOID LEUKAEMIA PATIENTS OF PAKISTANI ORIGIN TO TYROSINE KINASE INHIBITOR
Abstract
Chronic myelogenous leukaemia is a disease in which bone marrow produces too many white blood cells. It is more common in middle age and its incidence is rare in children. Imatinib is the standard first-line treatment in chronic myeloid leukaemia. It improved the prognosis with lesser side effects. Our point of interest is to highlight its role in the paediatric age group. we present case series of a patient with chronic myeloid leukaemia responsive to imatinib. Because of the rare incidence of chronic myeloid leukaemia in this age room limited studies to explore the role of treatment modalities in the paeds group. Our case series highlights imatinib’s effectiveness in treatment and improving the prognosis of the disease in this age group.References
Leung WY, Cheuk DK, Cheng FW, Leung AW, Chiu KH, Ho KK, et al. Outcome prediction of chronic myeloid leukaemia (CML) in children. Ann Hematol 2022;101(8):1677–88.
Suttorp M, Webster Carrion A, Hijiya N. Chronic myeloid leukaemia in children: Immune function and vaccinations. J Clin Med 2021;10(18):4056.
Al-Ghemlas I, Al-Daama S, Aqueel H, Siddiqui K, El-Solh H, Omer H, et al. Outcome of pediatric chronic myeloid leukaemia with management focusing on the monitoring of BCR-ABL fusion gene transcript levels. Int J Pediatr Adolesc Med 2022;9(3):160–4.
Hijiya N, Suttorp M. How I treat chronic myeloid leukaemia in children and adolescents. Blood 2019;133(22):2374–84.
Kaehler M, Cascorbi I. Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukaemia. Front Pharmacol 2021;12:696960.
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM. Determination of the Cut- off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients. Drug Des Devel Ther 2022;16:1595–1604.
Amouei A, Daeian N, Khezrnia SS, Mansouri A, Hadjibabaie M. Imatinib Efficacy, Safetyand Resistancein Iranian Patients with Chronic Myeloid Leukaemia: A Review of Literature. Int J Hematol Oncol Stem Cell Res 2021;15(2):114–31.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukaemia patients in real-life clinical practice. Blood Cancer J 2021;11(2):16.
Yaqub S, Zafar A, Latif MA, Ahmad Z, Bano K, Khokhar MA. Clinicopathological characteristics of CML in children and young adults. J Clin Oncol 2021;39(15_Suppl):e19029.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Syed Yar Muhammad Shah, Ajmal, Darakhshan Nawaz, Aiman Usman Lodhi, Jawad ur Rehman, Rehman Bahadar, Zaheer Ahmad, Faizan Babnaras
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
